Table 2

Effects of an antisense c-myc P(S)ODN on c-mycmRNA, c-Myc protein, and CYP expression

Treatmentc-myc mRNAc-Myc ProteinCYP mRNACYP ProteinTotal CYP
CYP2C11CYP3ACYP2C11CYP3A
% control % control cpm cpm % control % control nmol/mg protein
Control100  ± 31100  ± 8816  ± 1841813  ± 186100  ± 11100  ± 60.12  ± 0.01
IL-2214  ± 422-a 149  ± 112-a 344  ± 412-a 1192  ± 2902-a 63  ± 192-a 61  ± 92-a 0.08  ± 0.022-a
IL-2 + sense151  ± 54152  ± 162-a 179  ± 61a,b 998  ± 3042-a 65  ± 152-a 71  ± 42-a 0.09  ± 0.02
IL-2 + antisense29  ± 14a,b,c 86  ± 10b,c 500  ± 1642-c 1448  ± 35774  ± 1698  ± 8b,c 0.12  ± 0.022-c

After cell attachment, hepatocytes were cultured for 24 h with DOTAP and with or without IL-2 (350 U/ml) and a sense or antisense c-myc P(S)ODN (2 μM). Laser densitometry was used to quantify c-myc mRNA on Northern blots, c-Myc protein on immunoblots of immunoprecipitated proteins revealed by an ECL system, and CYP proteins on immunoblots of microsomal proteins revealed with an ECL system. CYP2C11 and CYP3A mRNAs were assessed by RT-PCR in the presence of [32P]deoxycytidine triphosphate. Total CYP was measured from CO-difference spectrum of dithionite-reduced cell lysates. Results are mean ± S.E.M. for five cultures.

  • 2-a Different from control (P < .05).

  • 2-b Different from IL-2 (P < .05).

  • 2-c Different from IL-2 + sense c-myc P(S)ODN (P < .05).